Evaluation of the Anti-Plaque Effect of a Resveratrol-Based Mouthwash Using a 24-Hour Plaque Re-Growth

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-25
SponsorUniversity of Baghdad

About this trial

Dental plaque is a biofilm that accumulates on tooth surfaces and is a primary factor in the development of gingival inflammation. While toothbrushing remains the main method for plaque control, the effectiveness of mechanical oral hygiene depends largely on individual compliance and technique. As a result, mouthwashes are commonly used as adjunctive chemical plaque control agents.

Chlorhexidine gluconate is an effective anti-plaque mouthwash, but its use is associated with undesirable effects that may limit patient acceptance. Resveratrol is a naturally derived compound with reported antimicrobial and anti-biofilm properties, suggesting its potential use as an alternative chemical plaque control agent.

This randomized, double-blind, placebo-controlled, three-period crossover clinical trial aims to evaluate the short-term anti-plaque effect of a resveratrol-based mouthwash by measuring supragingival plaque regrowth over a 24-hour period in periodontally healthy individuals. The effects of the resveratrol-based mouthwash will be compared with 0.12% chlorhexidine (CHX) and a placebo mouthwash under standardized conditions without mechanical oral hygiene

Eligibility criteria

Qualifiers

Age between 18 and 30 years

Systemically healthy individuals

Presence of at least 20 natural teeth

Clinically healthy gingiva with no signs of gingivitis or periodontitis

Disqualifiers

Presence of gingivitis or periodontitis

Active dental caries requiring treatment

History of periodontal therapy within the previous 6 months

Use of antibiotics, anti-inflammatory drugs, or antiseptic mouthwashes within the previous 3 months

Trial design

Treatments tested in this trial

  • Resveratrol-Based Mouthwash
  • Chlorhexidine Gluconate 0.12 % Mouthwash
  • Placebo mouthwash

Treatment groups

20 Participants
are divided into 3 treatment groups

Sponsors and collaborators